No Data
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), Revolution Medicines (RVMD)
Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026